Korea Investment CORP Acquires 413,201 Shares of Kenvue Inc. $KVUE

Key Points

• Korea Investment CORP increased its stake in Kenvue Inc. by 49.1% in Q1, now owning approximately 1,254,799 shares worth $30.09 million.
• Kenvue announced a quarterly dividend increase to $0.2075 per share, yielding 3.9%, with a payout ratio of 112.16%.
• The company reported earnings of $0.29 per share for the last quarter, beating expectations, while revenue decreased by 4% year-over-year to $3.84 billion.

Korea Investment CORP grew its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 49.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,254,799 shares of the company's stock after buying an additional 413,201 shares during the quarter. Korea Investment CORP owned approximately 0.07% of Kenvue worth $30,090,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Pittenger & Anderson Inc. acquired a new stake in shares of Kenvue in the first quarter valued at about $30,000. TruNorth Capital Management LLC bought a new position in Kenvue in the first quarter valued at approximately $36,000. Clal Insurance Enterprises Holdings Ltd increased its position in shares of Kenvue by 378.5% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock worth $39,000 after purchasing an additional 1,287 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich increased its position in shares of Kenvue by 120.6% during the 1st quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company's stock worth $41,000 after purchasing an additional 929 shares during the last quarter. Finally, Continuum Advisory LLC raised its stake in shares of Kenvue by 2,071.1% during the 1st quarter. Continuum Advisory LLC now owns 1,954 shares of the company's stock worth $47,000 after purchasing an additional 1,864 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Kenvue Stock Performance

Shares of KVUE traded up $0.1550 during midday trading on Friday, reaching $21.5950. 8,620,226 shares of the stock were exchanged, compared to its average volume of 18,631,350. The stock's 50 day simple moving average is $21.52 and its 200 day simple moving average is $22.43. The company has a market cap of $41.44 billion, a P/E ratio of 29.18, a PEG ratio of 3.10 and a beta of 0.83. Kenvue Inc. has a twelve month low of $19.75 and a twelve month high of $25.17. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping analysts' consensus estimates of $0.28 by $0.01. The business had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. Kenvue's revenue for the quarter was down 4.0% compared to the same quarter last year. During the same period last year, the firm earned $0.32 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th will be given a dividend of $0.2075 per share. This is a positive change from Kenvue's previous quarterly dividend of $0.21. This represents a $0.83 annualized dividend and a yield of 3.8%. The ex-dividend date of this dividend is Wednesday, August 13th. Kenvue's dividend payout ratio (DPR) is currently 112.16%.

Wall Street Analysts Forecast Growth

KVUE has been the subject of several analyst reports. Barclays decreased their target price on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research note on Tuesday, July 15th. Bank of America decreased their price objective on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a research report on Tuesday, July 15th. Zacks Research upgraded Kenvue to a "strong sell" rating in a research note on Monday, August 11th. Royal Bank Of Canada reduced their price objective on shares of Kenvue from $24.00 to $22.00 and set a "sector perform" rating for the company in a research report on Friday, August 8th. Finally, UBS Group decreased their price objective on shares of Kenvue from $25.00 to $23.00 and set a "neutral" rating on the stock in a report on Thursday, July 17th. Five investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Kenvue has a consensus rating of "Hold" and a consensus target price of $24.38.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.